Visualitzant O - Articles científics per títol

p27Kip1 V109G as a biomarker for CDK4/6 inhibitors indication in hormone receptor–positive breast cancer

Mouron, Silvana; Bueno, MJ; Muñoz, Manuel; Torres, Raul; Rodriguez, Sandra; Apala, Juan V.; Malumbres Martinez, Marcos (Oxford University Press, 2023-04)

Palbociclib and ribociclib in breast cancer: consensus workshop on the management of concomitant medication

Ahmad Diaz, Faten; Villanueva, Rafael; Valdivia Vadell, Carolina; Palomino-Doza, Julián; Ruiz, Ada; Azaro Pedrazzoli, Analía Beatriz; Aguilar Company, Juan; Martín Pérez, Anastasio; Escriva de Romaní Muñoz, Santiago Ignacio; Alcalde Rodrigo, Maria; Ruiz Camps, Isabel; Bellet Ezquerra, Meritxell; Reyes López, Victoria (SAGE Publications, 2019-05-10)

Palbociclib Rechallenge for Hormone Receptor-Positive/HER-Negative Advanced Breast Cancer: Findings from the Phase II BioPER Trial

Albanell, Joan; Pérez-García, José Manuel; Gil-Gil, Miguel J.; Ruiz Borrego, Manuel; Comerma Blesa, Laura; Bellet Ezquerra, Meritxell; Curigliano, Giuseppe (American Association for Cancer Research, 2023-01-04)

Palbociclib with Fulvestrant or Letrozole in Endocrine-Sensitive Patients with HR-Positive/HER2-Negative Advanced Breast Cancer: A Detailed Safety Analysis of the Randomized PARSIFAL Trial

Pérez-García, José Manuel; Dalenc, Florence; Gil-Gil, Miguel J.; Ruiz Borrego, Manuel; Di Cosimo, Serena; Bellet Ezquerra, Meritxell (Oxford University Press, 2023-01)

Pan-Asian adapted ESMO Clinical Practice Guidelines for the diagnosis, treatment and follow-up of patients with endometrial cancer

Koppikar, Smruti; OAKNIN, ANA; Babu, K. Govind; Lorusso, Domenica; Gupta, S.; Wu, L.-Y. (Elsevier, 2023-02)

Pan-cancer Analysis of Homologous Recombination Repair–associated Gene Alterations and Genome-wide Loss-of-Heterozygosity Score

Westphalen, C Benedikt; Fine, Alexander D.; André, Fabrice; Ganesan, Shridar; Heinemann, Volker; Rouleau, Etienne; Mateo Valderrama, Joaquim (American Association for Cancer Research, 2022-04-01)

Pan-cancer efficacy of pralsetinib in patients with RET fusion–positive solid tumors from the phase 1/2 ARROW trial

Cassier, Phillippe A.; Siena , Salvatore; Garralda Cabanas, Elena; Paz-Ares, Luis; Garrido, Pilar; Subbiah, Vivek (Nature Research, 2022-08)

Pan-cancer whole-genome comparison of primary and metastatic solid tumours

Movasati, Ali; Brunner, Sascha Remy; Nguyen, Luan; Van Hoeck, Arne; Martínez-Jiménez, Francisco; Priestley, Peter; Cuppen, Edwin (Nature Portfolio, 2023-06)

Patient-Centered Outcomes in ARIEL3, a Phase III, Randomized, Placebo-Controlled Trial of Rucaparib Maintenance Treatment in Patients With Recurrent Ovarian Carcinoma

Oza, Amit M.; Lorusso, Domenica; Oaknin Benzaquen, Ana Mazaltob; Dean, Andrew; Colombo, Nicoletta; Aghajanian, Carol (American Society of Clinical Oncology, 2020-10-20)

Patient-Centric Approaches for Phase I Combination Trials Come on Stage

Hernando-Calvo, Alberto; GARRALDA, Elena (American Association for Cancer Research, 2023-08-04)

Patient-derived preclinical models to develop immunotherapies

Seoane, Joan (Wiley, 2023-07)

Patient-Reported Health-Related Quality of Life in KEYNOTE-604: Pembrolizumab or Placebo Added to Etoposide and Platinum as First-Line Therapy for Extensive-Stage SCLC

Kim, Hye Ryun; Gottfried, Maya; Peters, Solange; Csoszi, Tibor; Awad, Mark; NAVARRO, ALEJANDRO (Elsevier, 2023-11)

Patient-reported Outcomes and Quality of Life in Anemic and Symptomatic Patients With Myelofibrosis: Results From the MOMENTUM Study

Harrison, Claire; McLornan, Donal; McMullin, Mary Frances; mesa, ruben; Palmer, Jeanne; Fox, Maria Laura; Gupta, Vikas (Wolters Kluwer Health, 2023-11)

Patient-reported outcomes and tolerability in patients receiving ripretinib versus sunitinib after treatment with imatinib in INTRIGUE, a phase 3, open-label study

Gelderblom, Hans; Jones, Robin; Blay, Jean-Yves; George, Suzanne; von Mehren, Margaret ; Zalcberg, John; Serrano, Cesar (Elsevier, 2023-07-20)

Patient-reported outcomes from the randomized phase 3 CROWN study of first-line lorlatinib versus crizotinib in advanced ALK-positive non-small cell lung cancer

Iadeluca, Laura; Shaw, Alice Tsang; de Marinis, Filippo; Felip Font, Enriqueta; Solomon, Benjamin; Bauer, Todd; Mazieres, Julien (Elsevier, 2022-12)

Patient-reported outcomes in individuals with advanced gastrointestinal stromal tumor treated with ripretinib in the fourth-line setting: analysis from the phase 3 INVICTUS trial

Schöfski, Patrick; Heinrich, Michael C.; Bauer, Sebastian; Serrano Garcia, César; Gelderblom, Hans; George, Suzanne; Zalcberg, John (BMC, 2022-12-13)

Patterns of inflammation, microstructural alterations, and sodium accumulation define multiple sclerosis subtypes after 15 years from onset

Ricciardi, Antonio; Kanber, Baris; Prados, Ferran; Yiannakas, Marios; Solanky, Bhavana; Grussu, Francesco (Frontiers Media, 2023-03-23)

PBRM1 mutations might render a subtype of biliary tract cancers sensitive to drugs targeting the DNA damage repair system

Zimmer, Kai; Kocher, Florian; Untergasser, Gerold; Kircher, Brigitte; Amann, Arno; Baca, Yasmine; Macarulla, Teresa; Tabernero, Josep (Nature Portfolio, 2023-07-03)

PCIG: a web-based application to explore immune–genomics interactions across cancer types

Pedrola Gómez, Anna; Franch-Exposito, Sebastia; Lahoz, Sara; Esteban-Fabró, Roger; Bassaganyas, Laia; Camps, Jordi; Dienstmann, Rodrigo (Oxford University Press, 2022-04-15)

PD-1 Blockade in Anaplastic Thyroid Carcinoma

Wirth, Lori J.; Ernst, Thomas; Lin, Chia-Chi; Capdevila Castillon, Jaume; Ponce Aix, Santiago; Ramlau, Rodryg (American Society of Clinical Oncology, 2020-08-10)

Scientia. Dipòsit d'Informació Digital del Departament de Salut

Visualitzant VHIO - Articles científics per títol

p27Kip1 V109G as a biomarker for CDK4/6 inhibitors indication in hormone receptor–positive breast cancer

Palbociclib and ribociclib in breast cancer: consensus workshop on the management of concomitant medication

Palbociclib Rechallenge for Hormone Receptor-Positive/HER-Negative Advanced Breast Cancer: Findings from the Phase II BioPER Trial

Palbociclib with Fulvestrant or Letrozole in Endocrine-Sensitive Patients with HR-Positive/HER2-Negative Advanced Breast Cancer: A Detailed Safety Analysis of the Randomized PARSIFAL Trial

Pan-Asian adapted ESMO Clinical Practice Guidelines for the diagnosis, treatment and follow-up of patients with endometrial cancer

Pan-cancer Analysis of Homologous Recombination Repair–associated Gene Alterations and Genome-wide Loss-of-Heterozygosity Score

Pan-cancer efficacy of pralsetinib in patients with RET fusion–positive solid tumors from the phase 1/2 ARROW trial

Pan-cancer whole-genome comparison of primary and metastatic solid tumours

Patient-Centered Outcomes in ARIEL3, a Phase III, Randomized, Placebo-Controlled Trial of Rucaparib Maintenance Treatment in Patients With Recurrent Ovarian Carcinoma

Patient-Centric Approaches for Phase I Combination Trials Come on Stage

Patient-derived preclinical models to develop immunotherapies

Patient-Reported Health-Related Quality of Life in KEYNOTE-604: Pembrolizumab or Placebo Added to Etoposide and Platinum as First-Line Therapy for Extensive-Stage SCLC

Patient-reported Outcomes and Quality of Life in Anemic and Symptomatic Patients With Myelofibrosis: Results From the MOMENTUM Study

Patient-reported outcomes and tolerability in patients receiving ripretinib versus sunitinib after treatment with imatinib in INTRIGUE, a phase 3, open-label study

Patient-reported outcomes from the randomized phase 3 CROWN study of first-line lorlatinib versus crizotinib in advanced ALK-positive non-small cell lung cancer

Patient-reported outcomes in individuals with advanced gastrointestinal stromal tumor treated with ripretinib in the fourth-line setting: analysis from the phase 3 INVICTUS trial

Patterns of inflammation, microstructural alterations, and sodium accumulation define multiple sclerosis subtypes after 15 years from onset

PBRM1 mutations might render a subtype of biliary tract cancers sensitive to drugs targeting the DNA damage repair system

PCIG: a web-based application to explore immune–genomics interactions across cancer types

PD-1 Blockade in Anaplastic Thyroid Carcinoma

Coneix Scientia

Guies i ajudes

Directe a...

Coneix Scientia

Guies i ajudes

Directe a...

Visualitzant VHIO - Articles científics per títol

p27Kip1 V109G as a biomarker for CDK4/6 inhibitors indication in hormone receptor–positive breast cancer ﻿

Palbociclib and ribociclib in breast cancer: consensus workshop on the management of concomitant medication ﻿

Palbociclib Rechallenge for Hormone Receptor-Positive/HER-Negative Advanced Breast Cancer: Findings from the Phase II BioPER Trial ﻿

Palbociclib with Fulvestrant or Letrozole in Endocrine-Sensitive Patients with HR-Positive/HER2-Negative Advanced Breast Cancer: A Detailed Safety Analysis of the Randomized PARSIFAL Trial ﻿

Pan-Asian adapted ESMO Clinical Practice Guidelines for the diagnosis, treatment and follow-up of patients with endometrial cancer ﻿

Pan-cancer Analysis of Homologous Recombination Repair–associated Gene Alterations and Genome-wide Loss-of-Heterozygosity Score ﻿

Pan-cancer efficacy of pralsetinib in patients with RET fusion–positive solid tumors from the phase 1/2 ARROW trial ﻿

Pan-cancer whole-genome comparison of primary and metastatic solid tumours ﻿

Patient-Centered Outcomes in ARIEL3, a Phase III, Randomized, Placebo-Controlled Trial of Rucaparib Maintenance Treatment in Patients With Recurrent Ovarian Carcinoma ﻿

Patient-Centric Approaches for Phase I Combination Trials Come on Stage ﻿

Patient-derived preclinical models to develop immunotherapies ﻿

Patient-Reported Health-Related Quality of Life in KEYNOTE-604: Pembrolizumab or Placebo Added to Etoposide and Platinum as First-Line Therapy for Extensive-Stage SCLC ﻿

Patient-reported Outcomes and Quality of Life in Anemic and Symptomatic Patients With Myelofibrosis: Results From the MOMENTUM Study ﻿

Patient-reported outcomes and tolerability in patients receiving ripretinib versus sunitinib after treatment with imatinib in INTRIGUE, a phase 3, open-label study ﻿

Patient-reported outcomes from the randomized phase 3 CROWN study of first-line lorlatinib versus crizotinib in advanced ALK-positive non-small cell lung cancer ﻿

Patient-reported outcomes in individuals with advanced gastrointestinal stromal tumor treated with ripretinib in the fourth-line setting: analysis from the phase 3 INVICTUS trial ﻿

Patterns of inflammation, microstructural alterations, and sodium accumulation define multiple sclerosis subtypes after 15 years from onset ﻿

PBRM1 mutations might render a subtype of biliary tract cancers sensitive to drugs targeting the DNA damage repair system ﻿

PCIG: a web-based application to explore immune–genomics interactions across cancer types ﻿

PD-1 Blockade in Anaplastic Thyroid Carcinoma ﻿

Coneix Scientia

Guies i ajudes

Directe a...

Coneix Scientia

Guies i ajudes

Directe a...

p27Kip1 V109G as a biomarker for CDK4/6 inhibitors indication in hormone receptor–positive breast cancer

Palbociclib and ribociclib in breast cancer: consensus workshop on the management of concomitant medication

Palbociclib Rechallenge for Hormone Receptor-Positive/HER-Negative Advanced Breast Cancer: Findings from the Phase II BioPER Trial

Palbociclib with Fulvestrant or Letrozole in Endocrine-Sensitive Patients with HR-Positive/HER2-Negative Advanced Breast Cancer: A Detailed Safety Analysis of the Randomized PARSIFAL Trial

Pan-Asian adapted ESMO Clinical Practice Guidelines for the diagnosis, treatment and follow-up of patients with endometrial cancer

Pan-cancer Analysis of Homologous Recombination Repair–associated Gene Alterations and Genome-wide Loss-of-Heterozygosity Score

Pan-cancer efficacy of pralsetinib in patients with RET fusion–positive solid tumors from the phase 1/2 ARROW trial

Pan-cancer whole-genome comparison of primary and metastatic solid tumours

Patient-Centered Outcomes in ARIEL3, a Phase III, Randomized, Placebo-Controlled Trial of Rucaparib Maintenance Treatment in Patients With Recurrent Ovarian Carcinoma

Patient-Centric Approaches for Phase I Combination Trials Come on Stage

Patient-derived preclinical models to develop immunotherapies

Patient-Reported Health-Related Quality of Life in KEYNOTE-604: Pembrolizumab or Placebo Added to Etoposide and Platinum as First-Line Therapy for Extensive-Stage SCLC

Patient-reported Outcomes and Quality of Life in Anemic and Symptomatic Patients With Myelofibrosis: Results From the MOMENTUM Study

Patient-reported outcomes and tolerability in patients receiving ripretinib versus sunitinib after treatment with imatinib in INTRIGUE, a phase 3, open-label study

Patient-reported outcomes from the randomized phase 3 CROWN study of first-line lorlatinib versus crizotinib in advanced ALK-positive non-small cell lung cancer

Patient-reported outcomes in individuals with advanced gastrointestinal stromal tumor treated with ripretinib in the fourth-line setting: analysis from the phase 3 INVICTUS trial

Patterns of inflammation, microstructural alterations, and sodium accumulation define multiple sclerosis subtypes after 15 years from onset

PBRM1 mutations might render a subtype of biliary tract cancers sensitive to drugs targeting the DNA damage repair system

PCIG: a web-based application to explore immune–genomics interactions across cancer types

PD-1 Blockade in Anaplastic Thyroid Carcinoma